[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemodialysis-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemodialysis-complication":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,68,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642829","comparison-of-tunneled-cuffed-dialysis-catheters-versus-arteriovenous-fistulae-in-elderly-or-multimorbid-patients-100642829",false,"NCT07649083","Comparison of Tunneled Cuffed Dialysis Catheters Versus Arteriovenous Fistulae in Elderly or Multimorbid Patients","Inclusion Criteria:\n\n* Aged ≥60 years or \\\u003C60 years with a CCI Score \\>6\n* Patients with CKD G5 A1-3 with indication for hemodialysis\n* Stable clinical condition\n* Eligibility for both arteriovenous fistula on the upper extremities and TCC\n* Availability for follow-up\n* Written informed consent\n\nExclusion Criteria:\n\n* Uncontrolled infection and\u002For CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl) at screening\n* Poor overall health or malignancy not in remission at screening\n* Major surgery within 12 weeks before screening\n* Pre-existent vascular access\n* Patient not eligible for any one of the vascular access options\n* Endovascular arteriovenous fistula","ALL","18 Years","99 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients are randomly assigned to a study group. Depending on the study group, either an arteriovenous fistula or tunneled cuffed catheter (TCC) will be implanted, followed by continuous evaluation of the patients during the first year after initiating the vascular access. The evaluation includes statistical evaluation of all events, including loss of access, thrombosis, infection, loss of patency, increase in co-morbidities, e.g. congestive heart failure as well as quality of life. The implantation of the TCC is a standard procedure and it will be used only in accordance with the approved instructions of use on subjects who have signed an informed consent form. The surgery is a standard operation and it will be performed by specialized surgeons on subjects who have signed an informed consent form (No grafts will be used; implantation of a standard TCC, used at the Department of Nephrology). Both, an arteriovenous fistula or a TCC, will be used for routine chronic haemodialysis",[26,27,28,29,30],"End Stage Renal Failure, Hemodialysis","Vascular Access","Fistulas Arteriovenous","Haemodialysis Complication","Haemodialysis Patients","NOT_YET_RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":20},"2026-08-01",{"date":39,"type":20},"2030-12-31",{"name":41,"class":42},"Medical University of Vienna","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100641241","impact-of-a-tunneled-hemodialysis-catheter-with-endexo-technology-on-catheter-dysfunction-compared-with-historical-catheter-dysfunction-data-in-standard-catheters-100641241","NCT07655544","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters (Silicone or Polyurethane): A Pilot Study","Inclusion Criteria:\n\n* Adult patients aged greater than 18 years\n* Written informed consent\n* Requirement for hemodialysis using a tunneled dialysis catheter\n\nExclusion Criteria:\n\n* Children aged less than 18 years\n* Uncontrolled infection; defined as positive blood culture in the past seven days before catheter insertion and\u002F or elevated C-reactive protein \\[CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl)\\] at screening",{"count":51,"type":20},50,[23],"There is evidence that central venous catheters made of the permanent and non-eluting integral polymer Endexo® are more resistant to intraluminal thrombosis. This has a direct reducing effect on catheter malfunctions. Indirectly, due to reduced handling of the dysfunctional catheter, this may lead to a diminished rate of catheter related infections. Since catheter malfunctions and infections represent leading complications in a dialysis population, dialysis catheters produced with Endexo® technology have the potential to have beneficial clinical effects. In addition to improving patient outcomes, this could also reduce overall costs. In this pilot study the tunneled hemodialysis catheter BioFlo Duramax with Endexo® technology (Merit Medical, Utah, USA) will be compared with historical catheter dysfunction rates in standard tunneled dialysis catheters (silicone or polyurethane) in chronic dialysis population.",[55,29,27,56,57,58,59,60],"Haemodialysis","Vascular Access Complication","ESRD (End Stage Renal Disease)","Dialysis Access Dysfunction","Dialysis Catheter","Dialysis Catheter Infections",{"date":62,"type":35},"2026-06-18",{"date":37,"type":20},{"date":65,"type":20},"2027-12-31",{"name":41,"class":42},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":15,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":67},"100286122","sodium-deposition-in-soft-tissues-of-patients-with-kidney-disease-100286122","NCT03004547","Sodium Deposition in Soft Tissues of Patients with Kidney Disease","Evaluation of Sodium Deposition in Soft Tissues of Patients with Kidney Disease and Its Association with Patient Symptomatology","Inclusion Criteria:\n\n* Age greater than or equal to 6 years\n* For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy\n* For patients with CKD stage 1-5: CKD stage 1-5 and no indications to start dialysis\n* For heart failure patients: with or without renal dysfunction\n* For healthy controls: lack of kidney disease, heart failure, liver cirrhosis, and peripheral edema\n\nFor subsequent visits (must meet 1 of the below indicators):\n\n* Change in dialysis prescription\n* Change in renal replacement therapy modality\n* Change in medication\n* Parathyroidectomy\n* Intervention added to or removed from dialysis (i.e. such as but not limited exercise, cooling, and ischemic preconditioning)\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or intending pregnancy\n* Unable to give consent or understand written information\n* Contraindication to MRI study",true,"6 Years",{"count":78,"type":20},400,"OBSERVATIONAL","Sodium (Na+) hemostasis is abnormal in CKD patients, and this element can be deposited in the skin, muscle, and skeleton - to cope with long term sodium loading. It is known that sodium stored in this non-osmotically active way, is profoundly inflammatory. Furthermore, inflammation has been associated with several uremic symptoms. The investigators will use novel Na+ MRI imaging to examine the Na+ deposition in the skin, muscle, and skeleton of five groups:1) chronic in-center hemodialysis patients, 2) chronic peritoneal dialysis patients, 3) adult and paediatric patients with CKD stage 1-5 and 4) heart failure patients with and without renal dysfunction 5) sex and age-matched healthy adult and paediatric controls. Additionally, they will investigate the association between sodium deposition in these tissues with uremic symptomatology and biochemical markers of metabolism.",[29],[83,84],"Sodium","Soft Tissues","RECRUITING","2025-02-10",{"date":88,"type":35},"2025-02-12",{"date":90,"type":35},"2018-03-05",{"date":92,"type":20},"2026-02-28",{"name":94,"class":42},"Chris McIntyre",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100518993","novel-cardiovascular-biomarkers-in-patients-with-kidney-disease-100518993","NCT06037759","Novel Cardiovascular Biomarkers in Patients With Kidney Disease","CBKD","Inclusion Criteria:\n\nPatients aged≥45 years (or ≥18 with a history of diabetes). b. Cases: Incident haemodialysis patients c. A comparative arm of peritoneal dialysis patients and CKD 3-4 (not on dialysis) with hypertension as a key risk factor for CVD.\n\nd. Capable of understanding the purpose and risks of the study, fully informed, and given informed consent.\n\nExclusion Criteria:\n\n1. Patients with pre-existing heart disease will be excluded.\n2. Patients with active cancer.",{"count":103,"type":20},100,"Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as they should. End-stage kidney failure (ESKD) is the final, irreparable stage of chronic kidney disease (CKD), where kidney function has worsened, so the kidneys can no longer function independently.\n\nAt this stage, dialysis is required to remove waste products and excess fluid from the blood. There are two types of dialysis. In haemodialysis (HD), blood is pumped out of the body to an artificial kidney machine and returned to the body by tubes that connect a person to the machine. In peritoneal dialysis (PD), the inside lining of the belly acts as a natural filter. PD has the advantage of being gentler on the heart. HD causes significant stress to the heart by reducing the blood flow to the heart muscle, resulting in heart failure, irregular rhythms, and eventually sudden heart death. A large observational study showed that HD patients had 48% worse survival in the first two years than PD patients.\n\nSeveral molecules ('biomarkers') can be detected in blood and inform doctors of heart damage. Studying the form and function of proteins (Proteomics), including how they work and interact with each other inside cells in patients, could help identify the onset of heart problems. HD patients are also prone to body fat changes (cholesterol\u002Flipids). Due to high cholesterol, there is build-up on the walls of arteries, causing their hardening. In HD patients, this process is faster due to abnormalities in lipid structure. Therefore, studying the heart biomarkers, protein, and lipid makeup of HD patients may help to find people at substantial risk of heart and vascular problems and if they are likely to become unwell due to these heart problems.",[29,106],"Major Adverse Cardiac Events",[108,109,55,110,106],"Chronic Kidney Disease","End Stage Kidney Disease","Biomarkers","2023-09-14",{"date":113,"type":35},"2023-09-18",{"date":115,"type":20},"2023-11-01",{"date":117,"type":20},"2026-11-01",{"name":119,"class":120},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV"]